drugset / Trial / NCT00313183
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
RandomizedCrossoverSingle-blindTreatment
Summary
This study will be the first evaluation of Symlin in adolescent subjects with type 1 diabetes mellitus and is designed to evaluate the blood levels (pharmacokinetics), biochemical and physiological effects (pharmacodynamics), and safety and tolerability of Symlin in these subjects.
Timeline
- Start
- 2006-04
- Primary completion
- 2007-08
- Completion
- 2007-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pramlintide | Peptide | 15 ug | Subcutaneous |
| Subject | Pramlintide | Peptide | 30 ug | Subcutaneous |